Exact Sciences

The company said it will use part of the proceeds to repurchase some of its senior notes due in January 2025, and the rest for corporate purposes.

The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.

The index, which outperformed the Dow Jones and the Nasdaq this month, gained 11 percent and rebounded from its 11 percent loss in December.

The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.

Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.

Biomatrica's sample collection tubes ensure quality preservation of circulating tumor DNA and cells, promoting high-quality liquid biopsy results, Exact said.

Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.